BioVex Group, Inc. – BioVex is a pre-revenues and pre-profit clinical-stage biotechnology company focused on the development and future commercialization of targeted treatments for cancer and the prevention of infectious disease. BioVex had numerous series of preferred stock with various liquidation preferences. Foxboro Consulting Valuation specialist provided an independent opinion as to the fair market value of the common stock and of the underlying stock options of the Company in compliance with provisions of Statement of Financial Accounting Standards 123(R) Share-based Payment (“FAS 123(R)”), and in compliance with IRC Section 409A.

Aeris Therapeutics, Inc. – Aeris Therapeutics is a  pre-profit clinical-stage biotechnology company focused on the development and future commercialization of treatments for patients with pulmonary disease. Aeris had numerous series of preferred stock with various liquidation preferences. Foxboro Consulting Valuation specialist provided an independent opinion as to the fair market value of the common stock and of the underlying stock options of the Company in compliance with provisions of Statement of Financial Accounting Standards 123(R) Share-based Payment (“FAS 123(R)”), and in compliance with IRC Section 409A.

Anesthesia Safety Products, LLC – Anesthesia Safety Products, which was founded in April of 2005, is a medical device company, engaged in the development and commercialization of an airtrap device which uses disposable cartridges. ASP’s product is intended to be an inexpensive, noninvasive compact monitor, alarm and a flow arrestor mechanism that will prevent the dangerous introduction of air into venous systems through IV devices. Foxboro Consulting Valuation specialist provided an independent opinion as to the fair market value of the owners’ equity.

Pioneer Surgical Technology, Inc. – Pioneer Surgical Technology made an offer to purchase the merge with Angstrom Medica, Inc. The merger transaction involved a combination of common stock, earn-out, and the assumption of certain liabilities. Foxboro Consulting Valuation specialist was retained by the Board of Directors of Angstrom Medica, Inc. to determine the fair market value of the common stock of Pioneer Surgical Technology for purposes of facilitating the merger transaction.

Bio-Engineering Networks, Inc. (BioEngine) – BioEngine has created the world’s first  vascularized, implantable bioengineered live assist device incorporating human liver cells. Its patents are based on 20 years of extensive research and headed by a pioneer in the organ engineering field in collaboration with Massachusetts GeneralHospital, MIT, Draper  Laboratory, and the ExOne Company.  The founders of BioEngine had the opportunity to license technology from MGH designed to augment the gas exchange function of a human lung. The Board of Directors of BioEngine negotiated a Collaboration Agreement with a company formed to pursue the opportunity, involving the sharing of technology and resources.  Foxboro Consulting Valuation specialist provided a financial review opinion on this Collaboration Agreement to the management and Board of Director of BioEngine. This company was formed and financed with a focused strategy of developing the lung technology, while  BioEngine realized economic and strategic benefits from the Collaboration Agreement.

BioModels, LLC – Biomodels was planning to offer a “profits only interest” in future operations of the Company to one of the principals. In doing this, it was necessary for the owners to determine the fair market value of the Company’s business enterprise and related owners’ equity.  Foxboro Consulting valuation specialist determined the fair market value of BioModels’  business enterprise, as well as the  fair market value of the owners’ equity in the Company.

Learning Services Corporation – LSC provides long-term care and rehabilitation services for patients with severe brain injury.  Foxboro Consulting Valuation specialist determined the fair market value of the common stock as part of the Company’s financial decision-making. 

Athena Health, Inc. – Athena Health, Inc. is high-end physician billing, physician practice management and electronic medical record services provider. Our Managing Director – Valuations provided business valuation and merger and acquisition advisory services to Athena Health, Inc.

EnVivo – EnVivi is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous disorders currently focusing on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and spinocerebellar ataxias. Foxboro Consulting Valuation specialist was hired to advise  the Board of Directors of EnVivo and to provide a fairness opinion for the special committee of the Board of Directors of EnVivo as part of their Series C financing led by existing investor Fidelity Biosciences. EnVivo used the $24.0 million funding to advance several promising programs into clinical trials including an alpha-7  nicotine receptor for cognition enhancement in Alzheimer’s disease and schizophrenia.

Northeast Health Systems – Northeast Health Systems is a regional provider of acute care and outpatient healthcare services in the Cape Ann area of northeastern Massachusetts. Our Managing Director of Valuations provided business valuation and  physician practice acquisition advisory services to Northeast Health Systems in their effort to build a primary care network.